Company Overview

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers.  The Company currently has two drug candidates in development:

  • CUDC-907, an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.

  • CA-170, an orally-available, small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.

Curis is engaged in a broad collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology.  As part of this collaboration, Curis has the exclusive license to CA-170, and has also selected a second program that focuses on small molecule antagonists of PD-1 and TIM3 pathways, including compounds that target PD-L1/TIM3 immune checkpoints.  Curis has also licensed the exclusive rights to orally-available small molecule inhibitors of the IRAK4 kinase, including the development candidate CA-4948 from Aurigene.

The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge® (vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Roche and Genentech are continuing Erivedge®’s clinical development in less severe forms of BCC as well as in other diseases including idiopathic pulmonary fibrosis, or IPF, and myelofibrosis.